Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IMMUNOTHERAPY

Advancing oncolytic virus therapy by understanding the biology

Talimogene laherparepvec (T-VEC) is an oncolytic virus approved for the treatment of patients with recurrent melanoma. Now, a recent study in patients with primary cutaneous B cell lymphoma confirms prior results in melanoma and reveals new mechanisms of action. Herein, we discuss these findings and their implications for expanding the role of oncolytic viruses.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Multimodal mechanisms of action associated with oncolytic virus therapy.

References

  1. Kaufman, H. L. et al. Oncolytic viruses: a new class of immunotherapy. Nat. Rev. Drug Disc. 18, 642–662 (2015).

    Article  Google Scholar 

  2. Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788 (2015).

    Article  CAS  Google Scholar 

  3. Andtbacka, R. H. et al. Patterns of clinical response with Talimogene laherparepvec in patients with melanoma treated in the OPTiM Phase III clinical trial. Ann. Surg. Oncol. 23, 4169–4177 (2016).

    Article  Google Scholar 

  4. Kaufman, H. L. et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIC and IV melanoma. Ann. Surg. Oncol. 17, 718–730 (2010).

    Article  Google Scholar 

  5. Macedo, N. et al. Clinical landscape of oncolytic virus research in 2020. J. Immunother. Cancer. 8, e001486 (2020).

    Article  Google Scholar 

  6. Ramelyte, E. et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer Cell https://doi.org/10.1016/j.ccell.2020.12.022 (2021).

    Article  PubMed  Google Scholar 

  7. Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra32 (2014).

    Article  Google Scholar 

Download references

Acknowledgements

The authors wish to thank G. Iodice for helpful conversations and review of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Howard L. Kaufman.

Ethics declarations

Competing interests

H.L.K. is an employee of Immuneering Corp. D.M. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kaufman, H.L., Maciorowski, D. Advancing oncolytic virus therapy by understanding the biology. Nat Rev Clin Oncol 18, 197–198 (2021). https://doi.org/10.1038/s41571-021-00490-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-021-00490-4

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing